This home study is an archived webinar from the APhA2017 Annual Meeting held in San Francisco, CA.
You have to weigh the advantages of new and emerging products. For insulin, these include U300 insulin, U500 insulin, and insulin degludec; while these agents expand therapeutic options, they also complicate decisions for many pharmacists. Now, pharmacists must consider not only administration, storage, and counseling, but also access—because cost may be a barrier. During this session, experts will use patient cases to demonstrate the appropriate use of various insulin therapies and describe strategies that support patient access.
After participating in "Beyond Oral Antidiabetics: Insulin Therapy Options and Combinations (Home Study)", the pharmacist will be able to:
- Compare and contrast the characteristics of recently approved forms of insulin.
- Explain the potential roles of recently improved insulins in the management of type 1 and type 2 diabetes.
- Describe strategies to minimize insulin-induced hypoglycemia, including patient education tools.
- Select insulin administration aids based on patient characteristics.
- Describe skills that are effective for educating patients who are resistant to taking insulin.
Activity Type: Knowledge-based
Target Audience: Pharmacists
Learning Level: Level 3
To obtain credit for "Beyond Oral Antidiabetics: Insulin Therapy Options and Combinations (Home Study)" complete the assessment with a grade of 70% or better, complete the evaluation and CLAIM credit. Participants will need to have a valid pharmacist.com username and password to claim credit. After your credit has been claimed, please visit CPE monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. All exam questions are randomized and may not appear in the same order as printed. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial Release Date: March 26, 2017
Expiration date: March 26, 2020 - NO CREDIT GRANTED AFTER THIS DATE
"Beyond Oral Antidiabetics: Insulin Therapy Options and Combinations (Home Study)" is an archived webinar education activity for pharmacists developed by the American Pharmacists Association.
Jennifer Trujillo declares that she serves on an advisory board for Sanofi.
Stuart Haines, PHARMD declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.
APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, please visit the APhA website at www.pharmacist.com/apha-disclosures. Conflicts of interest have been resolved through content review by Helen Sairany, PharmD, BCACP, Associate Director of Content Development at the American Pharmacists Association.
The fee for this activity is $29 for APhA members and $49 for non-members.
Computer and Internet access is required to complete this activity. Please visit our website to view the Technology System Requirements to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-17-058-H04-P||0.2 CEUs||March 26, 2017 - March 26, 2020|